Treatment Related Impact Measure for Diabetes (TRIM-D)

Novo Nordisk (Denmark)

Distributed by Mapi Research Trust


Distributed by Mapi Research Trust

Basic description

The development process for the TRIM-Diabetes has been an iterative one, beginning in 2002.


Novo Nordisk (Denmark)

TRIM-D © Novo Nordisk, August 2008.
To measure treatment related impact on subjects of diabetes medication and diabetes devices
Therapeutic area
  • Nutritional and Metabolic Diseases
  • Endocrine System Diseases
Therapeutic indication

Diabetes Mellitus

Type 1 – IDDM, Type 2 – Insulin-requiring patients
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Brod M, Hammer M, Christensen T, Lessard S, Bushnell DM. Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health Qual Life Outcomes. 2009 Sep 9;7:83 (Full Text Article)

Brod M, Christensen T, Hammer M, Busk AK, Bushnell DM. Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures. Qual Life Res. 2011 Nov;20(9):1513-8. Epub 2011 Mar 19 (Full Text article)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use


Novo Nordisk (Denmark)

Contact information

Mapi Research Trust
27 rue de la Villette
69003 Lyon
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.


Original language(s)

  • English for the USA


The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.


Afrikaans for South Africa L
Albanian for MACEDONIA*
Arabic for Algeria* L
Arabic for Israel L
Arabic for Kuwait*
Arabic for Saudi Arabia*
Arabic for the United Arab Emirates*
Assamese for India*
Bengali for India L
Bosnian for Bosnia and Herzegovina*
Bulgarian for Bulgaria L
Cebuano for the Philippines*
Chinese for Hong Kong L
Chinese for Malaysia L
Croatian for Bosnia and Herzegovina* L
Croatian for Croatia L
Czech for Czech Republic* L
Danish for Denmark L
Dutch for Belgium (Flemish) L
Dutch for the Netherlands*
English for Australia L
English for Canada* L
English for Hong Kong L
English for India L
English for Malaysia L
English for South Africa L
English for the Philippines* L
English for the UK* L
Estonian for Estonia*
Filipino for the Philippines*
Finnish for Finland L
French for Algeria* L
French for Belgium
French for Canada*
French for France*
German for Austria L
German for Germany*
German for Switzerland L
Greek for Greece L
Gujarati for India
Hebrew for Israel L
Hiligaynon for the Philippines*
Hindi for India
Hungarian for Hungary*
Ilocano for the Philippines*
Italian for Italy*
Japanese for Japan L
Kannada for India L
Korean for South Korea L
Latvian for Latvia*
Lithuanian for Lithuania*
Macedonian for Macedonia
Malay for Malaysia L
Malayalam for India
Mandarin for China L
Mandarin for Malaysia
Mandarin for Taiwan L
Marathi for India L
Norwegian for Norway L
Oriya for India
Persian for Iran L
Polish for Poland*
Portuguese for Brazil L
Portuguese for Portugal L
Punjabi for India L
Romanian for Romania L
Russian for Estonia*
Russian for Israel
Russian for Latvia*
Russian for Lithuania*
Russian for Russia*
Russian for Ukraine L
Serbian for Bosnia and Herzegovina*
Serbian for Serbia L
Slovak for Slovakia L
Slovenian for Slovenia L
Sotho for South Africa*
Spanish for Argentina L
Spanish for Chile*
Spanish for Mexico L
Spanish for Peru*
Spanish for Spain* L
Spanish for the USA*
Swedish for Finland L
Swedish for Sweden
Tagalog for the Philippines*
Tamil for India L
Tamil for Malaysia L
Telugu for India
Thai for Thailand L
Turkish for Turkey* L
Ukrainian for Ukraine L
Urdu for India* L
Vietnamese for Vietnam* L
Vietnamese for the USA*
Xhosa for South Africa*
Zulu for South Africa*
* Performed by Mapi/ICON
L Has undergone a Linguistic Validation methodology

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services


Conditions to implement in electronic applications

Please refer to the "Contact and conditions of use" tab

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us